MCL1 and neoplasm: Therefore, it is urgent to improve the targeted binding efficiency of NSC 260594 to mitochondria and reduce the potential off-target effects, thereby enhancing the anti-tumor activity of Mcl-1 inhibitors and reducing toxicity.